Perrigo Feels Ill Effects Of Mild Cold Season, Excess OTC Capacity
This article was originally published in The Tan Sheet
The private labeler lowered its full-year revenue guidance, noting weak cough/cold/flu OTC sales. Perrigo built up excess capacity to take advantage of recalled Johnson & Johnson OTCs, and now is shifting some capacity in response to a Novartis plant shutdown.
You may also be interested in...
McNeil Remediation Stretches Out, Dragging On J&J Consumer Sales
The latest delay in Johnson & Johnson’s remediation of its McNeil OTC manufacturing pushes back FDA’s review of the Fort Washington, Pa., facility to “late 2013.” The firm’s Q1 results saw the worldwide consumer business fall 2.4% to $3.60 billion, including negative currency exchange effects.
Perrigo Relies On New Products For Fiscal Second-Half Boost
Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.